Cognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Up 26.2% in February

Cognition Therapeutics, Inc. (NASDAQ:CGTXGet Free Report) was the recipient of a large growth in short interest in the month of February. As of February 29th, there was short interest totalling 126,800 shares, a growth of 26.2% from the February 14th total of 100,500 shares. Based on an average trading volume of 234,900 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.6% of the company’s stock are sold short.

Cognition Therapeutics Trading Up 2.2 %

Shares of NASDAQ CGTX opened at $1.82 on Friday. Cognition Therapeutics has a one year low of $0.90 and a one year high of $3.49. The firm has a market capitalization of $59.02 million, a PE ratio of -2.30 and a beta of 1.67. The business has a 50-day moving average price of $2.11 and a two-hundred day moving average price of $1.63.

Institutional Investors Weigh In On Cognition Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Steward Financial Group LLC purchased a new stake in shares of Cognition Therapeutics during the 3rd quarter worth about $58,000. BlackRock Inc. raised its stake in shares of Cognition Therapeutics by 54.8% in the 2nd quarter. BlackRock Inc. now owns 58,417 shares of the company’s stock valued at $107,000 after acquiring an additional 20,678 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of Cognition Therapeutics by 91.0% in the 4th quarter. Two Sigma Investments LP now owns 46,620 shares of the company’s stock valued at $98,000 after acquiring an additional 22,213 shares in the last quarter. Captrust Financial Advisors bought a new position in shares of Cognition Therapeutics in the 3rd quarter valued at approximately $95,000. Finally, Baird Financial Group Inc. raised its stake in shares of Cognition Therapeutics by 100.0% in the 3rd quarter. Baird Financial Group Inc. now owns 40,786 shares of the company’s stock valued at $77,000 after acquiring an additional 20,393 shares in the last quarter. 23.43% of the stock is owned by hedge funds and other institutional investors.

About Cognition Therapeutics

(Get Free Report)

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.

See Also

Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.